Debra Head shot.jpg

Debra Levine, PhD, LP

Insurance: Blue Care Network (including M Premier), Blue Cross Blue Shield (except Blue Cross Complete and Medicare Plus Blue) and PHP/Michigan Cares insurance

Dr. Levine completed her doctoral training in clinical psychology at the University of Michigan-Ann Arbor (PhD program) and Michigan’s Mary A. Rackham Institute (clinical psychology internship) in 2014. In her graduate work, Dr. Levine focused on treating and researching anxiety and related disorders, with a particular focus on disseminating empirically supported treatments for Social Anxiety Disorder, Panic Disorder, and OCD to individuals who would not ordinarily seek psychological treatments. From 2014-2016, Dr. Levine worked as an advanced postdoctoral clinical psychology fellow at the University of Michigan/VA Ann Arbor Consortium, where she treated veterans with a range of anxiety disorders in the primary care mental health-integration clinic and engaged in research designed to improve access to empirically supported anxiety and mood disorder treatments for veterans.

Dr. Levine’s goal in therapy is to create a safe, secure, and collaborative environment to help you and/or your family achieve your personal goals and improve your anxiety and related concerns. She uses current scientific evidence to design customized treatments and strives to help clients develop skills for reducing current anxiety symptoms and preventing future relapse. Dr. Levine has received extensive training in a variety of empirically supported treatments for anxiety and mood disorders, including Cognitive Behavioral Therapy (CBT) and Exposure and Response Prevention (ERP) for OCD.  Dr. Levine is also well-versed in Habit Reversal Therapy for body focused repetitive disorders, Acceptance and Commitment Therapy (ACT), and Interpersonal Therapy (IPT).

Dr. Levine is a member of the Association of Anxiety and Depressive Disorders (ADAA) and the American Psychological Association (APA) and has presented locally, nationally and internationally on how to improve access to empirically supported treatments for anxiety disorders.